GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gene Biotherapeutics Inc (OTCPK:CRXM) » Definitions » Selling, General, & Admin. Expense

Gene Biotherapeutics (Gene Biotherapeutics) Selling, General, & Admin. Expense : $1.05 Mil (TTM As of Dec. 2020)


View and export this data going back to . Start your Free Trial

What is Gene Biotherapeutics Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Gene Biotherapeutics's selling, general, & admin. expense for the three months ended in Dec. 2020 was $0.42 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2020 was $1.05 Mil.


Gene Biotherapeutics Selling, General, & Admin. Expense Historical Data

The historical data trend for Gene Biotherapeutics's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gene Biotherapeutics Selling, General, & Admin. Expense Chart

Gene Biotherapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.20 1.78 0.91 0.59 1.05

Gene Biotherapeutics Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Dec17 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.11 0.19 0.32 0.42

Competitive Comparison of Gene Biotherapeutics's Selling, General, & Admin. Expense

For the Biotechnology subindustry, Gene Biotherapeutics's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gene Biotherapeutics's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gene Biotherapeutics's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Gene Biotherapeutics's Selling, General, & Admin. Expense falls into.



Gene Biotherapeutics Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gene Biotherapeutics  (OTCPK:CRXM) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Gene Biotherapeutics Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Gene Biotherapeutics's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Gene Biotherapeutics (Gene Biotherapeutics) Business Description

Traded in Other Exchanges
N/A
Address
11230 Sorrento Valley Road, Suite 220, San Diego, CA, USA, 92121
Gene Biotherapeutics Inc is a clinical stage biotechnology company focused on pre-clinical, clinical, and commercialization of angiogenic gene therapy biotherapeutics for strategic niche markets primarily for the treatment of cardiovascular disease. The company's lead product candidate Generx is an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease.
Executives
Andrew M Leitch director 6615 CALLE PONTE BELLA, RANCHO SANTA FE CA 92091
Murray H Hutchison director C/O CADIZ INC., 550 SOUTH HOPE STREET, 2850, LOS ANGELES CA 90071
Dennis Mulroy officer: Chief Financial Officer
Ronald I Simon other: Former Director 485 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Robert N Weingarten director, officer: PRESIDENT and CFO 5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367

Gene Biotherapeutics (Gene Biotherapeutics) Headlines